- Home
- FOUR vs CLDX Comparison
FOUR vs CLDX Comparison
Compare FOUR & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOUR | CLDX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | FOUR | CLDX |
|---|---|---|
| Price | $42.03 | $38.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 10 |
| Target Price | ★ $79.05 | $46.60 |
| AVG Volume (30 Days) | ★ 1.8M | 633.0K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,180,000,000.00 | $12,743,000.00 |
| Revenue This Year | $23.83 | $111.39 |
| Revenue Next Year | $14.30 | $235.85 |
| P/E Ratio | $27.53 | ★ N/A |
| Revenue Growth | 25.50 | ★ 87.78 |
| 52 Week Low | $34.56 | $22.10 |
| 52 Week High | $88.50 | $45.14 |
Technical Indicators
Market Signals| Indicator | FOUR | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 46.33 |
| Support Level | $39.78 | $28.51 |
| Resistance Level | $46.17 | $40.30 |
| Average True Range (ATR) | 2.88 | 1.27 |
| MACD | 0.07 | -0.24 |
| Stochastic Oscillator | 43.27 | 41.76 |
Price Performance
Historical ComparisonAbout FOUR Shift4 Payments Inc.
Shift4 Payments Inc is an independent provider of software and payment processing solutions in the U.S., expanding internationally. Its payments platform offers integrated products and services across in-store, online, mobile and tablet-based channels, including end-to-end payment processing, merchant acquiring services, a proprietary omni-channel gateway, eCommerce capabilities, and reporting tools. The company distributes its services through internal sales teams and partners, including independent software vendors (ISVs) and value-added resellers (VARs). Revenue is predominantly recurring, derived mainly from processing fees and subscription revenue from POS software, business intelligence tools and other technology solutions. The company derives maximum revenue from the United States.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.